探索胆道恶性瘤的二线治疗中的分子机制
QianLin Liu1,2, PengFei Zhang1,2, Qiu Li1,2
1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, 610041 Chengdu, Sichuan, China.
Discovery medicine
|January 26, 2024
概括
胆道癌症是一个重大的挑战,往往是晚期诊断的. 本综述探讨了对晚期疾病的新兴二线治疗方法,重点关注分子标和病理学.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 分子病理学分子病理学
背景情况:
- 胆道恶性瘤占胃肠道癌症的3%.
- 早期诊断至关重要,但由于潜伏的疾病性质,经常错过,限制了手术选择.
- 吉姆西塔宾加西斯普拉丁是治疗晚期疾病的第一线药物,但第二线选择仍未确定.
研究的目的:
- 审查关于胆道恶性瘤的当前文献.
- 探索晚期胆道癌的潜在二线治疗策略.
- 为了将治疗选择与分子病原和瘤病理相关联.
主要方法:
- 关于胆道癌症现有研究的文献综述.
- 对胆道恶性瘤发展中的分子机制的分析.
- 基于分子洞察力的潜在向疗法的评估.
主要成果:
- 了解分子通路的进步为治疗提供了新的途径.
- 针对性治疗对晚期胆道癌症有希望.
- 分子病变发生有助于开发新的治疗策略.
结论:
- 了解分子病理学是开发有效的二线治疗的关键.
- 向疗法是晚期胆道恶性瘤的一个有希望的前沿.
- 对分子驱动因素的进一步研究将完善胆道癌症的治疗选择.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K


